Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 5, 2011 - Issue 2
Submit an article Journal homepage
173
Views
18
CrossRef citations to date
0
Altmetric
Special Report

Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds

Guy Hagan Pulmonary Vascular Disease Unit, Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, CB23 3RE, UK; Pulmonary Vascular Disease Unit, Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, CB23 3RE, UK
&
Joanna Pepke-Zaba Pulmonary Vascular Disease Unit, Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, CB23 3RE, UK;[email protected]
Pages 163-171 | Published online: 09 Jan 2014

References

  • Simonneau G, Robbins I, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.54, 43–54 (2009).
  • Koshland DE. The molecule of the year. Science258, 1861 (1992).
  • Palmer RMJ, Ferrige AG, Moncada S. Nirtic oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature327, 524–526 (1987).
  • Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev.43, 109–142 (1991).
  • Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesise nitric oxide from L-arginine. Nature333, 664–666 (1988).
  • Palmer RMJ, Moncada S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem. Biophys. Res. Commun.158, 348–352 (1989).
  • Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N. Engl. J. Med.329, 2002–2012 (1993).
  • Hirata Y, Emori T, Eguchi S et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J. Clin. Invest.91(4), 1367–1373 (1993).
  • Archer SL, Huang JM, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP dependent protein kinase. Proc. Natl Acad. Sci. USA91, 7583–7587 (1994).
  • Lungberg JO, Weitzberg E, Gladwin MT. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Discov.7(2), 156–157 (2008).
  • Coggins MP, Bloch KD. Nitric oxide in the pulmonary vasculature. Arterioscler. Thromb. Vasc. Biol.27, 1877–1885 (2007).
  • Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.333(4), 214–221 (1995).
  • Xue C, Johns RA. Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.333, 1642–1644 (1995).
  • Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med.159, 1925–1932 (1999).
  • Mason NA, Springall DR, Burke M et al. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J. Path.185, 313–318 (1998).
  • Rengasamy A, Johns RA. Characterisation of endothelium derived relaxing factor from bovine cerebellum and mechanisms of modulation by high and low oxygen tensions, J. Pharmacol. Exp. Ther.259, 310–316 (1991).
  • Hughes R, Tong J, Oates C, Lordan J, Corris PA. Evidence for systemic endothelial dysfunction in patients and first order relatives with pulmonary arterial hypertension. Chest128, 617S (2005).
  • Romero LI, Zhang D, Cooke JP et al. Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vasc. Med.5, 147–158 (2000).
  • Dinh-Xuan AT, Higenbottam TW, Clelland C, Pepke-Zaba J, Cremona G, Wallwork J. Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger’s syndrome. Br. J. Pharmacol.99(1), 9–10 (1990).
  • Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary haemodynamics. Circulation87, 440–446 (1993).
  • Dinh-Xuan AT, Higenbottam TW, Clelland CA et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease, N. Engl. J. Med.324(22), 1539–1547 (1991).
  • Bogdan M, Humbert M, Francoual J et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax53, 1059–1062 (1998).
  • Matthias G, Zheng C, Egon W, Fiehn W, Ulmer HE. Plasma Levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J. Cardiovasc. Pharm.37(4), 489–492 (2001).
  • Kielstein JT, Bode-Böger SM, Hesse G et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol.25, 1414–1418 (2005).
  • Pullamsetti S, Kiss L, Ghofrani HA et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J.19(9), 1175–1177 (2005).
  • Skoro-Sajer N, Mittermayer F, Panzenboeck A et al. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med.176(11), 1154–1160 (2007).
  • Kaneko FT, Arrolinga AC, Dweik RA et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am. J. Respir. Crit. Care Med.158(3), 917–923 (1998).
  • Ozkan M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung179(4), 233–243 (2001).
  • Xu W, Kaneko FT, Zheng S. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J.18(14), 1746–1748 (2004).
  • Aicher A, Heeschen, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med.9(11), 1370–1376 (2003).
  • Thum T, Fraccarollo D, Thum S et al. Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress. Arterioscler. Thromb. Vasc. Biol.27(4), 748–754 (2007).
  • Diller G, van Eijl S, Okonko O et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation117(23), 3020–3030 (2008).
  • Frostell C, Fratacci MD, Waid JC et al. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation83, 2038–2047 (1991).
  • Pepke-Zaba J, Higenbottam TW, Dinh-Zuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasoldilatation in pulmonary hypertension. Lancet388(8776), 1173–1174 (1991).
  • Borland C. Endothelium in control. Br. Heart J.66, 405 (1991).
  • Frampton MW, Morrow PE, Cox C et al. Effects of nitrogen dioxide exposure on pulmonary function and airway reactivity in normal controls. Am. Rev. Respir. Dis.143, 522–527 (1991).
  • Clutton-Brock J. Two cases of poisoning by contanimation of nitrous oxide with higher oxides of nitrogen during anaesthesia. Br. J. Anaesth.39, 388–392 (1967).
  • Miller OI, Tang SF, Keech A et al. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet346, 51–52 (1995)
  • Christenson J, Lavoie A, O’Connor M et al. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am. J. Respir. Crit. Care Med.161(5), 1443–1449 (2000).
  • Lee JE, Hillier SC, Knoderer CA. Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J. Intensive Care Med.23(5), 329–334 (2008).
  • Roberts JD, Fineman JR, Morin FC et al. inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N. Engl. J. Med.336(9), 605–610 (1997).
  • Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The neonatal inhaled nitric oxide study group. N. Engl. J. Med.336(9), 597–604 (1997).
  • Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med.327(2), 76–71 (1992).
  • Post MC, Janssens S, Van de Werf F et al. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur. Heart J.25(18), 1651–1656 (2004).
  • Skoro-Sajer N, Hack N, Sadushi-Kolici R et al. Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study. Circulation119(2), 298–305 (2009).
  • Pérez-Peñate GM, Juliá-Serdà G, Ojeda-Betancort N et al. Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension. J. Heart Lung Trans.27(12), 1326–1332 (2008).
  • Channick R, Johnson FW, Williams PJ et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest109(6), 1545–1549 (1996).
  • Peinado VI, Barberà JA, Ramírez J. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am. J. Physiol. Lung Cell. Mol. Physiol.274(6), L908–L913 (1998).
  • Weitzenblum E, Hirth C, Ducolone A et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax36(10), 752–758 (1981).
  • Vonbank K, Ziesche R, Higgenbottam TW et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax58(4), 289–293 (2003).
  • Abbas A, Kakra H, Sadeghi A et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation72(4), 638–641 (2001).
  • Imanaka H, Miyano H, Takeuchi M et al. Effects of nitric oxide inhalation after pulmonary thromboendarterectomy for chronic pulmonary thromboembolism. Chest118(1), 39–46 (2000).
  • Fullteron D, Jones SD, Jaggers J et al. Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation. J. Thorac Cardiovasc. Surg.111(4), 753–763 (1996).
  • Keefer LK, Nims RW, Davies KM et al. “NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms, Methods Enzymol.268, 281–293 (1996).
  • Young KC, Ladino J, Navarrete C et al. The effect of a nebulized NO donor, DPTA/NO, on acute hypoxic pulmonary hypertension in newborn piglets. Biol. Neonate85(3), 195–202 (2004).
  • Hampl V, Tristani-Firouzi M, Hutsell TC. Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension. Cardiovasc. Res.31(1), 55–62 (1996).
  • Lam CF, Van Heerden PV, Blott J et al. The selective pulmonary vasodilatory effect of inhaled DETA/NO, a novel nitric oxide donor, in ARDS – a pilot human trial. J. Crit. Care19(1), 48–53 (2004).
  • Morris CR, Kato GJ, Poljakovic M et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA294(1), 81–90 (2005).
  • Ou Z, Wei W, Huang D et al.L-arginine restores endothelial nitric oxide synthase-coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats. Am. J. Physiol. Endocrinol. Metab.298(6), E1131–E1139 (2010).
  • Howell K, Costello CM, Sands M et al.L-arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol.296(6), L1042–L1050 (2009).
  • Morris CM, Morris SM, Hagar W et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am. J. Respir. Crit. Care Med.168(1), 63–69 (2003).
  • Nagaya N, Uematsu M, Oya H et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am. J. Respir. Crit. Care Med.163(4), 887–892 (2001).
  • Hunter CJ, Dejam A, Blood AB et al. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat. Med.10, 1122–1127 (2004).
  • Ingram TE, Pinder AG, Bailey DM et al. Low-dose sodium nitrite vasodilates hypoxic human pulmonary vasculature by a means that is not dependent on a simultaneous elevation in plasma nitrite. Am. J. Physiol. Heart Circ. Physiol.298(2), H331–H339 (2010).
  • Robbins IM, Hemnes AR, Gibbs SJ et al. Safety of sapropterin dihydrochloride (6R-BH4) in patients with pulmonary hypertension. Exp. Lung Res.37(1), 26–34 (2011).
  • Wharton J, Strange JW, Gigi M et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med.172(1), 105–115 (2005).
  • Nagendran J, Archer SL, Soliman D et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation116(3), 238–248 (2007).
  • Michelakis E, Tymchak W, Lien D et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation105, 2398–2403 (2002).
  • Zhao L, Mason NA, Morrell NW et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation104(4), 424–428 (2001).
  • Galiè N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Eng. J. Med.353(20), 2148–2157 (2005).
  • Galiè N, Brundage BH, Ghofrani HA et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation119, 2894–2903 (2009).
  • Gibbs JSR. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax63(Suppl. 2), 1–41 (2008).
  • Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J.30, 2493–2537 (2009).
  • Ghofrani HA, Rose F, Schermuly R et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol.42(1), 158–164 (2003).
  • Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am. J. Cardiol.96(9), 1334–1336 (2005).
  • Simonneau G, Rubin LJ, Galiè N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med.149(8), 521–553 (2008).
  • Suntharalingham J, Treacy CM, Doughty NJ et al. Long term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest134(2), 229–236 (2008).
  • De Santo LS, Mastroianni C, Romano G et al. Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients. Transplant. Proc.40(6), 2015–2018 (2008).
  • Holverda S, Rietema H, Bogaard HJ. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm. Pharm. Ther.21(3), 558–564 (2008).
  • Richalet J, Gratadour P, Robach P et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am. J. Respir. Crit. Care Med.171(3), 275–281 (2005).
  • Ghofani HA, Wiedemann R, Rose F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet360(9337), 895–900 (2002).
  • Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5´-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J. Card. Fail.14(3), 189–197 (2008).
  • Ramani FV, Park MH. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Drug Des. Devel. Ther.4, 61–70 (2010).
  • Archer S, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N. Engl. J. Med.361, 1864–1871 (2009).
  • Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildeanfil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am. J. Cardiol.83(5A), 21C–28C (1999).
  • Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood84(12), 4226–4233 (1994).
  • Schermuly RT, Stasch JP, Pullamsetti SS et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur. Respir. J.32, 881–891 (2008).
  • Ghofrani HA, Hoeper MM, Halank M et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a Phase II study. Eur. Respir. J.36(4), 792–799 (2010).
  • Wang X, Zhang F, Shang Y et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J. Am. Coll. Cardiol.49, 1566–1571 (2007).
  • Deng W, Bivalacqua TJ, Champion HC, Hellstrom WJ, Murthy SN, Kadowitz PJ. Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the lungs for pulmonary hypertension. Methods Mol. Biol.610, 309–321 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.